6th European Congress on Hematologic Malignancies from Clinical Science to Clinical Practice

26. 2. 2010 - 28. 2. 2010, InterContinental Carlton Cannes, Cannes, France

Registrace

Friday, 26 February 2010
13:00 Welcome and introduction

Session I: Myeloma
Moderator: Jesus San Miguel, MD and Bertrand Coiffier, MD

13:05
Overview of newly diagnosed patients
Speaker invited

13:20
DEBATE: First-line treatment in the transplant eligible patient
Jean-Luc Harousseau, MD
Antonio Palumbo, MD

13:50
Current and emerging options for relapsed myeloma
Jesus San Miguel, MD

14:10
DEBATE: Best salvage therapy for the relapsed patient
Meletios A. Dimopoulos, MD
Jesus San Miguel, MD

14:40
The role of VTE prophylaxis in myeloma
Antonio Palumbo, MD

15:00
Summary of the IMW consensus on response criteria and relevant outcomes
Joan Bladé, MD

15:15
Chair take-home points for the clinician

15:20
Break

Session II: Chronic Lymphocytic Leukemia
Moderator: Eva Kimby, MD, PhD

15:40
Role of the microenvironment in CLL
Speaker invited

16:00
Monoclonal B-cell lymphocytosis and CLL
Paulo Ghia, MD

16:20
Case discussion: Optimal management of the low risk patient
Speaker invited

16:50
Case discussion: Optimal therapy for the high risk patient
Speaker invited

17:20
DEBATE: Management of the double-refractory patient
Speakers invited

17:50
Panel discussion

18:00
Chair take-home points for the clinician and adjourn

Saturday, 27 February 2010
Session III: Follicular Lymphoma
Moderator: Gilles Salles, MD and Eva Kimby, MD, PhD

9:00
Role of the microenvironment in CLL
Speaker invited

9:20
Overview of maintenance therapy
Gilles Salles, MD

9:40
DEBATE: Is follicular lymphoma curable?
Michele Ghielmini, MD (no)
Christian Buske, MD (yes)

10:10
DEBATE: The role of stem cell transplant in patients with relapsed follicular lymphoma
Bertrand Coiffier, MD (for)
Rien van Oers, MD (against)

10:40
Panel discussion and chair take-home points for the clinician

10:50 Break
Saturday, 27 February 2010 (...cont'd)
Session IV: Mantle Cell Lymphoma
Moderator: Eva Kimby, MD, PhD

11:10
Biology of mantle cell lymphoma
Andrew Rosenward, MD

11:30
Case discussion: Mantle cell lymphoma therapy in young and old patients
Speaker invited

11:50
Maintenance therapy after first-line and second-line therapy in MCL
Michele Ghielmini, MD

12:10
DEBATE: Autologous versus allogeneic transplantation in mantle cell lymphoma
Speaker invited (auto)
Norbert Schmitz, MD (allo)

12:40
Panel discussion and chair take-home points for the clinician

13:00
Lunch

Session V: Aggressive B-cell Non-Hodgkin Lymphoma
Moderator: Bertrand Coiffier, MD and Michael Pfreundschuh, MD

14:30
Biology and treatment of bulky and mediastinal large B-cell lymphoma
Speaker invited

14:50
DEBATE: Prevention and treatment of central nervous system disease
Michael Pfreundschuh, MD
Speaker invited

15:20
DEBATE: Improving high-risk DLBCL in both the young and the elderly
Bertrand Coiffier, MD
Michael Pfreundschuh, MD

15:50
PROPOSITION: Same treatment for germinal centre (GC) and non-GC patients?
Speaker invited (no)
Speaker invited (yes)

16:10
Panel discussion and chair take-home points for the clinician

16:20
Break

Session VI: T-Cell Lymphoma
Moderator: Bertrand Coiffier, MD

16:40
Pathology overview of T-cell lymphoma
Andrew Rosenward, MD

17:00
Case discussion: Treatment of nasal type lymphoma (localized and disseminated)
Speaker invited

17:20
DEBATE: Transplantation in young patients
Speaker invited (for)
Nicolas Mounier, MD (against)

17:50
Panel discussion and chair take-home points for the clinician

18:00
Adjourn

Sunday, 28 February 2010
Session VII: Hodgkin’s Disease
Moderator: Andreas Engert, MD

9:00
Overview: Improving efficacy and reducing toxicity of localized HD
Andreas Engert, MD

9:20
Radiation in Hodgkin’s disease
Lena Specht, MD, PhD

9:40
Treatment of relapsing patients
Christophe Fermé, MD

10:00
Allogeneic transplantation
Norbert Schmitz, MD

10:20
Panel discussion and chair take-home points for the clinician

10:30
Break

Session VIII: SPECIAL SESSION –Acute Lymphoblastic Leukemia
Moderator: Dieter Hoelzer, MD

11:00
Recent diagnostic approaches and molecular genetics in acute lymphoblastic leukemia (ALL)
Speaker invited

11:25
New treatment options in adult ALL including targeted therapy
Dieter Hoelzer, MD

11:50
Update on achievements in childhood ALL
Speaker invited

12:15
Minimal residual disease: The most prognostic parameters to stratify and treat ALL
Nicola Gökbuget, MD

12:40
Panel discussion and chair take-home points for the clinician

13:00
Adjourn

Kontakt: meetings@imedex.com

Web: http://www.imedex....ements/a138-01.asp

  • Sdílejte na:
    • Facebook
    • Twitter
    • Del.icio.us
    • Digg
    • Google
    • Reddit
    • StumbleUpon
    • Live